XML 17 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Changes in Equity - USD ($)
$ in Thousands
Total Stockholder's Equity
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Treasury Stock
Deferred Compensation
Noncontrolling Interests
Total
Beginning Balance at Oct. 31, 2023 $ 682,493 $ 2 $ 2,199,704 $ (1,515,541) $ (1,672) $ (1,078) $ 1,078 $ 17,955 $ 700,448
Beginning Balance at (in shares) at Oct. 31, 2023   15,020,872              
Common stock issued, non-employee compensation 51   51           51
Common stock issued, non-employee compensation (in shares)   1,480              
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (926)   (926)           (926)
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)   41,173              
Share based compensation 2,876   2,876           2,876
Preferred dividends - Series B (800)   (800)           (800)
Effect of foreign currency translation 33       33       33
Adjustment for deferred compensation           (51) 51    
Adjustment for deferred compensation (in shares)   (1,480)              
Contributions received for sale of noncontrolling interest               25,122 25,122
Distribution to non-controlling interest               (236) (236)
Net Loss (19,793)     (19,793)       (24,606) (44,399)
Ending Balance at Jan. 31, 2024 663,934 $ 2 2,200,905 (1,535,334) (1,639) (1,129) 1,129 18,235 682,169
Ending Balance at (in shares) at Jan. 31, 2024   15,062,045              
Beginning Balance at Oct. 31, 2024 656,922 $ 2 2,300,031 (1,641,550) (1,561) (1,198) 1,198 10,687 $ 667,609
Beginning Balance at (in shares) at Oct. 31, 2024   20,375,932             20,375,932
Sale of common stock, net of fees 5,892   5,892           $ 5,892
Sale of common stock, net of fees (in shares)   690,711              
Common stock issued, non-employee compensation 82   82           82
Common stock issued, non-employee compensation (in shares)   8,335              
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (468)   (468)           (468)
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)   75,834              
Share based compensation 2,142   2,142           2,142
Preferred dividends - Series B (800)   (800)           (800)
Effect of foreign currency translation (232)       (232)       (232)
Adjustment for deferred compensation           (70) 70    
Adjustment for deferred compensation (in shares)   (7,040)              
Contributions received for sale of noncontrolling interest               4,000 4,000
Distribution to non-controlling interest               (600) (600)
Net Loss (28,326)     (28,326)       (4,060) (32,386)
Ending Balance at Jan. 31, 2025 $ 635,212 $ 2 $ 2,306,879 $ (1,669,876) $ (1,793) $ (1,268) $ 1,268 $ 10,027 $ 645,239
Ending Balance at (in shares) at Jan. 31, 2025   21,143,772             21,143,772